|
|
Binds to both Topoisomerase II (DNA Gyrase) and IV |
 |
| |
|
|
|
|
Increased potency against Gram Positive organisms compared with older Fluoroquinolones |
| |
|
|
| BICYCLIC SIDE CHAIN |
| |
|
|
|
|
Improves potency |
| |
|
|
|
|
Minimizes bacterial resistance |
| |
|
|
|
|
Only Moxifloxacin, however, has a Bicyclic side chain. This modification allows Moxifloxacin to inhibit bacterial cell’s efflux pump mechanism and allows the drug to stay in the pathogens for a longer period of time. The longer the drug stays in the cells, the greater the kill rate is. |
| |
|
|
